延长半衰期因子产品的转换注意事项。 - Suppr

Suppr

超能文献

Transition considerations for extended half-life factor products.

作者信息

Croteau S E, Neufeld E J

机构信息

Dana Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.

出版信息

Haemophilia. 2015 May;21(3):285-288. doi: 10.1111/hae.12683. Epub 2015 Apr 9.

DOI:10.1111/hae.12683

PMID:25855484

Abstract

摘要

相似文献

Transition considerations for extended half-life factor products.延长半衰期因子产品的转换注意事项。

Haemophilia. 2015 May;21(3):285-288. doi: 10.1111/hae.12683. Epub 2015 Apr 9.

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.采用群体药代动力学方法评估和解读甲型或乙型血友病个体患者的药代动力学特征：国际血栓与止血学会科学和标准化委员会的通讯

J Thromb Haemost. 2017 Dec;15(12):2461-2465. doi: 10.1111/jth.13867. Epub 2017 Nov 9.

Continuous infusion of coagulation factors: current opinion.凝血因子的持续输注：当前观点

Curr Opin Hematol. 2006 Sep;13(5):308-15. doi: 10.1097/01.moh.0000239701.32674.e0.

Stretching time.拉伸时间。

Sci Am. 2015 Jan;312(1):S8-10. doi: 10.1038/scientificamerican0115-s8.

Needles and needleless devices for infusion of anti-haemophilic factor concentrate: impact on protein structure and function.用于输注抗血友病因子浓缩物的针头和无针装置：对蛋白质结构和功能的影响。

Haemophilia. 2006 Jan;12(1):58-61. doi: 10.1111/j.1365-2516.2005.01168.x.

Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.增强半衰期因子 VIII 和 IX 在血友病治疗中的作用。

Br J Haematol. 2015 Jun;169(6):768-76. doi: 10.1111/bjh.13360. Epub 2015 Mar 7.

Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.美国血友病治疗中心为中重度血友病患者开出的延长半衰期因子浓缩物的地域差异和成本影响。

Haemophilia. 2019 Jul;25(4):668-675. doi: 10.1111/hae.13758. Epub 2019 Apr 17.

Treatment on demand--in vivo dose finding studies.按需治疗——体内剂量探索研究。

Haemophilia. 2003 Jul;9(4):360-7. doi: 10.1046/j.1365-2516.2003.00761.x.

Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).VIII 因子和 IX 因子检测在血友病患者输注后监测中的应用：法国 BIMHO 专家组（GFHT）指南。

Eur J Haematol. 2020 Aug;105(2):103-115. doi: 10.1111/ejh.13423. Epub 2020 May 27.

Is haemophilia prophylaxis achievable in the context of self-sufficiency?

Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 4:S71-5. doi: 10.1097/00001721-199412004-00019.

引用本文的文献

Current clinical applications of AAV-mediated gene therapy.腺相关病毒介导的基因治疗的当前临床应用。

Mol Ther. 2025 Jun 4;33(6):2479-2516. doi: 10.1016/j.ymthe.2025.04.045. Epub 2025 May 5.

Current Clinical Applications of In Vivo Gene Therapy with AAVs.腺相关病毒（AAV）体内基因治疗的临床应用现状。

Mol Ther. 2021 Feb 3;29(2):464-488. doi: 10.1016/j.ymthe.2020.12.007. Epub 2020 Dec 10.

Dental management of patients with haemophilia in the era of recombinant treatments: increased efficacy and decreased clinical risk.重组治疗时代血友病患者的牙科管理：疗效提高且临床风险降低。

BMJ Case Rep. 2019 Apr 8;12(4):e227974. doi: 10.1136/bcr-2018-227974.

The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries.患者与医疗保健专业人员在发达国家和发展中国家新型血友病治疗时代所扮演的角色。

Ther Adv Hematol. 2018 Jul 2;9(8):239-249. doi: 10.1177/2040620718784830. eCollection 2018 Aug.

Focusing in on use of pharmacokinetic profiles in routine hemophilia care.聚焦药代动力学特征在血友病常规治疗中的应用。

Res Pract Thromb Haemost. 2018 May 27;2(3):607-614. doi: 10.1002/rth2.12118. eCollection 2018 Jul.

Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.真实世界中血友病 B 患者接受标准半衰期和延长半衰期产品以及从标准半衰期产品转换为延长半衰期产品的凝血因子 IX 用量和相应支出的分析。

J Manag Care Spec Pharm. 2018 Jul;24(7):643-653. doi: 10.18553/jmcp.2018.17212. Epub 2018 Jan 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验